2018 Vaso-Occlusive Crisis Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Vaso-Occlusive Crisis Market
Vaso-occlusive crisis (VOCs) is one of the most common complications associated with Sickle cell disease (SCD). The disease occurs due to abnormal hemoglobin and is a painful and deadly situation. The cells that are affected by Vaso occlusive crisis deform into sickle shape that restricts them from free flow of blood, resulting in extreme pain and ultimately can lead to death. The disease is estimated to value at $356 million for pain management alone.
To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Vaso-Occlusive Crisis pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Vaso-Occlusive Crisis pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Vaso-Occlusive Crisis pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Vaso-Occlusive Crisis pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Vaso-Occlusive Crisis pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Vaso-Occlusive Crisis pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
1 TABLE OF CONTENTS
1.1 List of LIST OF FIGURES
1.2 List of Tables
2 VASO-OCCLUSIVE CRISIS PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Vaso-Occlusive Crisis Pipeline Snapshot
2.3 Vaso-Occlusive Crisis Pipeline by Phase
2.4 Vaso-Occlusive Crisis Pipeline by Company
2.5 Vaso-Occlusive Crisis Pipeline by Mechanism of Action
3 VASO-OCCLUSIVE CRISIS- COMPANY WISE PIPELINE ANALYSIS
ArQule, Inc.
AstraZeneca Plc
bluebird bio, Inc.
Global Blood Therapeutics Inc
Hillhurst Biopharmaceuticals Inc
Imara Inc
Modus Therapeutics Holding AB
Novartis AG
NuvOx Pharma LLC
Pfizer Inc
Prolong Pharmaceuticals LLC
Sancilio & Company Inc
Seattle Genetics, Inc.
Selexys Pharmaceuticals Corporation
4 VASO-OCCLUSIVE CRISIS R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN VASO-OCCLUSIVE CRISIS PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
1.1 List of LIST OF FIGURES
1.2 List of Tables
2 VASO-OCCLUSIVE CRISIS PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Vaso-Occlusive Crisis Pipeline Snapshot
2.3 Vaso-Occlusive Crisis Pipeline by Phase
2.4 Vaso-Occlusive Crisis Pipeline by Company
2.5 Vaso-Occlusive Crisis Pipeline by Mechanism of Action
3 VASO-OCCLUSIVE CRISIS- COMPANY WISE PIPELINE ANALYSIS
ArQule, Inc.
AstraZeneca Plc
bluebird bio, Inc.
Global Blood Therapeutics Inc
Hillhurst Biopharmaceuticals Inc
Imara Inc
Modus Therapeutics Holding AB
Novartis AG
NuvOx Pharma LLC
Pfizer Inc
Prolong Pharmaceuticals LLC
Sancilio & Company Inc
Seattle Genetics, Inc.
Selexys Pharmaceuticals Corporation
4 VASO-OCCLUSIVE CRISIS R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN VASO-OCCLUSIVE CRISIS PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
LIST OF FIGURES
Figure 1: Vaso-Occlusive Crisis Pipeline by Phase, H2- 2018
Figure 2: Vaso-Occlusive Crisis Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Vaso-Occlusive Crisis Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018
Figure 1: Vaso-Occlusive Crisis Pipeline by Phase, H2- 2018
Figure 2: Vaso-Occlusive Crisis Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Vaso-Occlusive Crisis Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018
LIST OF TABLES
Vaso-Occlusive Crisis Pipeline by Phase, H2- 2018
Vaso-Occlusive Crisis Pipeline by Companies, H2- 2018
Vaso-Occlusive Crisis Pipeline by Mechanism of Action, H2- 2018
Table 1: ArQule, Inc. Vaso-Occlusive Crisis Pipeline Drugs, H2- 2018
Table 2: AstraZeneca Plc Vaso-Occlusive Crisis Pipeline Drugs, H2- 2018
Table 3: bluebird bio, Inc. Vaso-Occlusive Crisis Pipeline Drugs, H2- 2018
Table 4: Global Blood Therapeutics Inc Vaso-Occlusive Crisis Pipeline Drugs, H2- 2018
Table 5: Hillhurst Biopharmaceuticals Inc Vaso-Occlusive Crisis Pipeline Drugs, H2- 2018
Table 6: Imara Inc Vaso-Occlusive Crisis Pipeline Drugs, H2- 2018
Table 7: Modus Therapeutics Holding AB Vaso-Occlusive Crisis Pipeline Drugs, H2- 2018
Table 8: Novartis AG Vaso-Occlusive Crisis Pipeline Drugs, H2- 2018
Table 9: NuvOx Pharma LLC Vaso-Occlusive Crisis Pipeline Drugs, H2- 2018
Table 10: Pfizer Inc Vaso-Occlusive Crisis Pipeline Drugs, H2- 2018
Table 11: Prolong Pharmaceuticals LLC Vaso-Occlusive Crisis Pipeline Drugs, H2- 2018
Table 12: Sancilio & Company Inc Vaso-Occlusive Crisis Pipeline Drugs, H2- 2018
Table 13: Seattle Genetics, Inc. Vaso-Occlusive Crisis Pipeline Drugs, H2- 2018
Table 14: Selexys Pharmaceuticals Corporation Vaso-Occlusive Crisis Pipeline Drugs, H2- 2018
Vaso-Occlusive Crisis Pipeline by Phase, H2- 2018
Vaso-Occlusive Crisis Pipeline by Companies, H2- 2018
Vaso-Occlusive Crisis Pipeline by Mechanism of Action, H2- 2018
Table 1: ArQule, Inc. Vaso-Occlusive Crisis Pipeline Drugs, H2- 2018
Table 2: AstraZeneca Plc Vaso-Occlusive Crisis Pipeline Drugs, H2- 2018
Table 3: bluebird bio, Inc. Vaso-Occlusive Crisis Pipeline Drugs, H2- 2018
Table 4: Global Blood Therapeutics Inc Vaso-Occlusive Crisis Pipeline Drugs, H2- 2018
Table 5: Hillhurst Biopharmaceuticals Inc Vaso-Occlusive Crisis Pipeline Drugs, H2- 2018
Table 6: Imara Inc Vaso-Occlusive Crisis Pipeline Drugs, H2- 2018
Table 7: Modus Therapeutics Holding AB Vaso-Occlusive Crisis Pipeline Drugs, H2- 2018
Table 8: Novartis AG Vaso-Occlusive Crisis Pipeline Drugs, H2- 2018
Table 9: NuvOx Pharma LLC Vaso-Occlusive Crisis Pipeline Drugs, H2- 2018
Table 10: Pfizer Inc Vaso-Occlusive Crisis Pipeline Drugs, H2- 2018
Table 11: Prolong Pharmaceuticals LLC Vaso-Occlusive Crisis Pipeline Drugs, H2- 2018
Table 12: Sancilio & Company Inc Vaso-Occlusive Crisis Pipeline Drugs, H2- 2018
Table 13: Seattle Genetics, Inc. Vaso-Occlusive Crisis Pipeline Drugs, H2- 2018
Table 14: Selexys Pharmaceuticals Corporation Vaso-Occlusive Crisis Pipeline Drugs, H2- 2018
